{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:27:23Z","timestamp":1771475243788,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In yellow fever (YF) endemic areas, measles, mumps, and rubella (MMR), and YF vaccines are often co-administered in childhood vaccination schedules. Because these are live vaccines, we assessed potential immune interference that could result from co-administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an open-label, randomized non-inferiority trial among healthy 1-year-olds in Misiones Province, Argentina. Children were randomized to one of three groups (1:1:1): Co-administration of MMR and YF vaccines (MMR<jats:sub>1<\/jats:sub>YF<jats:sub>1<\/jats:sub>), MMR followed by YF vaccine four weeks later (MMR<jats:sub>1<\/jats:sub>YF<jats:sub>2<\/jats:sub>), or YF followed by MMR vaccine four weeks later (YF<jats:sub>1<\/jats:sub>MMR<jats:sub>2<\/jats:sub>). Blood samples obtained pre-vaccination and 28 days post-vaccination were tested for immunoglobulin G antibodies against measles, mumps, and rubella, and for YF virus-specific neutralizing antibodies. Non-inferiority in seroconversion was assessed using a -5% non-inferiority margin. Antibody concentrations were compared with Kruskal-Wallis tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 851 randomized children, 738 were correctly vaccinated, had\u2009\u2265\u20091 follow-up sample, and were included in the intention-to-treat population. Non-inferior seroconversion was observed for all antigens (measles seroconversion: 97.9% in the MMR<jats:sub>1<\/jats:sub>YF<jats:sub>1<\/jats:sub> group versus 96.3% in the MMR<jats:sub>1<\/jats:sub>YF<jats:sub>2<\/jats:sub> group, a difference of 1.6% [90% CI -1.5, 4.7]; rubella: 97.9% MMR<jats:sub>1<\/jats:sub>YF<jats:sub>1<\/jats:sub> versus 94.7% MMR<jats:sub>1<\/jats:sub>YF<jats:sub>2<\/jats:sub>, a difference of 3.3% [-0.1, 6.7]; mumps: 96.7% MMR<jats:sub>1<\/jats:sub>YF<jats:sub>1<\/jats:sub> versus 97.9% MMR<jats:sub>1<\/jats:sub>YF<jats:sub>2<\/jats:sub>, a difference of -1.3% [-4.1, 1.5]; and YF: 96.3% MMR<jats:sub>1<\/jats:sub>YF<jats:sub>1<\/jats:sub> versus 97.5% YF<jats:sub>1<\/jats:sub>MMR<jats:sub>2<\/jats:sub>, a difference of -1.2% [-4.2, 1.7]). Rubella antibody concentrations and YF titers were significantly lower following co-administration; measles and mumps concentrations were not impacted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Effective seroconversion was achieved and was not impacted by the co-administration, although antibody levels for two antigens were lower. The impact of lower antibody levels needs to be weighed against missed opportunities for vaccination to determine optimal timing for MMR and YF vaccine administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>The study was retrospectively registered in ClinicalTrials.gov (NCT03368495) on 11\/12\/2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08114-1","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:48:15Z","timestamp":1679863695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina"],"prefix":"10.1186","volume":"23","author":[{"given":"Carla","family":"Vizzotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anal\u00eda","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Ranca\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Biscayart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pontoriero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cecilia","family":"Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirta","family":"Magari\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Reef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janeen","family":"Laven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Wannemuehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba Maria Ropero","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Erin","family":"Staples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"issue":"27","key":"8114_CR1","first-page":"269","volume":"88","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper -- June 2013. Wkly Epidemiol Rec. 2013;88(27):269\u201383.","journal-title":"Wkly Epidemiol Rec"},{"issue":"29","key":"8114_CR2","first-page":"301","volume":"86","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301\u201316.","journal-title":"Wkly Epidemiol Rec"},{"issue":"41","key":"8114_CR3","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1016\/j.vaccine.2014.07.076","volume":"32","author":"AS Wallace","year":"2014","unstructured":"Wallace AS, Mantel C, Mayers G, Mansoor O, Gindler JS, Hyde TB. Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine. 2014;32(41):5301\u201310.","journal-title":"Vaccine"},{"key":"8114_CR4","unstructured":"World Health Organization. Background paper on yellow fever vaccine: SAGE working group. https:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/april\/1_Background_Paper_Yellow_Fever_Vaccines.pdf?ua=1; 2013. (accessed 21 November 2021)"},{"issue":"37","key":"8114_CR5","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","volume":"29","author":"JR Nascimento Silva","year":"2011","unstructured":"Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327\u201334.","journal-title":"Vaccine"},{"issue":"8","key":"8114_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1473-3099(11)70147-5","volume":"11","author":"ES Jentes","year":"2011","unstructured":"Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11(8):622\u201332.","journal-title":"Lancet Infect Dis"},{"key":"8114_CR7","unstructured":"World Health Organization. Measles and Rubella SAGE working group: Background paper on immunologic response to measles-containing vaccines (MCVs) and yellow fever (YF) vaccines when co-administered. https:\/\/www.who.int\/immunization\/sage\/meetings\/2018\/october\/2_Co-administration_YF_MCV_vaccines_measles_session_yellow_book_doc.pdf?ua=1; 2018. (accessed 21 November 2021)"},{"key":"8114_CR8","unstructured":"World Health Organization. Reported estimates of yellow fever vaccine coverage Available from: https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/timeseries\/tscoverageyfv.html. (accessed 21 November 2021)"},{"key":"8114_CR9","unstructured":"Pan American Health Organization. Update on the yellow fever situation in the Americas and yellow fever vaccination. Itemid=270\u3008=en; 2019. https:\/\/www.paho.org\/hq\/index.php?option=com_docman&view=download&alias=50491-25-tag-final-report-2019&category_slug=tag-final-reports-1626&. (accessed 21 November 2021)."},{"key":"8114_CR10","unstructured":"Argentina Ministerio de Salud. Recomendaciones nacionales de vacunacion Argentina 2012. 0000000451cnt-2013-06_recomendaciones-vacunacion-argentina-2012.pdf (salud.gob.ar). ; 2012. (accessed 21 November 2021)"},{"key":"8114_CR11","volume-title":"Diagnostic procedures for viral, rickettsial, and chlamydial infections","author":"BJ Beaty","year":"1995","unstructured":"Beaty BJ, Calisher CH, Shope R. Arboviruses. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for viral, rickettsial, and chlamydial infections. Washington, D.C.: American Public Health Association; 1995."},{"key":"8114_CR12","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Geneva; 2010."},{"issue":"17","key":"8114_CR13","first-page":"205","volume":"92","author":"world Health Organization","year":"2017","unstructured":"world Health Organization. Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec. 2017;92(17):205\u201327.","journal-title":"Wkly Epidemiol Rec"},{"issue":"7","key":"8114_CR14","first-page":"51","volume":"82","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51\u201360.","journal-title":"Wkly Epidemiol Rec"},{"issue":"8","key":"8114_CR15","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","volume":"4","author":"E Clarke","year":"2016","unstructured":"Clarke E, Saidu Y, Adetifa JU, Adigweme I, Hydara MB, Bashorun AO, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in the Gambia. Lancet Glob Health. 2016;4(8):e534\u201347.","journal-title":"Lancet Glob Health"},{"issue":"45","key":"8114_CR16","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1016\/j.vaccine.2017.09.047","volume":"35","author":"C Goujon","year":"2017","unstructured":"Goujon C, Gougeon ML, Tondeur L, Poirier B, Seffer V, Despres P, et al. CHRONOVAC VOYAGEUR: a study of the immune response to yellow fever vaccine among infants previously immunized against measles. Vaccine. 2017;35(45):6166\u201371.","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"8114_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/cid\/civ603","volume":"61","author":"P Roy Chowdhury","year":"2015","unstructured":"Roy Chowdhury P, Meier C, Laraway H, Tang Y, Hodgson A, Sow SO, et al. Immunogenicity of Yellow Fever Vaccine Coadministered with MenAfriVac in Healthy Infants in Ghana and Mali. Clin Infect Dis. 2015;61(Suppl 5):586\u201393.","journal-title":"Clin Infect Dis"},{"key":"8114_CR18","doi-asserted-by":"crossref","unstructured":"Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO et al. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study.Lancet Infect Dis. 2019.","DOI":"10.2139\/ssrn.3346514"},{"key":"8114_CR19","unstructured":"Barrett ADT. Fractional dosing of yellow fever vaccines: review of vaccine potency & stability information, available evidence, and evidence gaps.SAGE meeting of October2016; Geneva2016."},{"key":"8114_CR20","doi-asserted-by":"crossref","unstructured":"Barrett ADT. Yellow Fever Vaccine: The Conundrum of 2 Doses, One Dose, or One-Fifth Dose to Induce and Maintain Protective Immunity.J Infect Dis. 2019.","DOI":"10.1093\/infdis\/jiz379"},{"issue":"4","key":"8114_CR21","first-page":"537","volume":"83","author":"D Mouchon","year":"1990","unstructured":"Mouchon D, Pignon D, Vicens R, Tu Ha T, Tekaia F, Teulieres L, et al. [The combined measles-yellow fever vaccination in african infants aged 6 to 10 months]. Bull Soc Pathol Exot. 1990;83(4):537\u201351.","journal-title":"Bull Soc Pathol Exot"},{"issue":"1","key":"8114_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0092-1157(89)90023-1","volume":"17","author":"M Lhuillier","year":"1989","unstructured":"Lhuillier M, Mazzariol MJ, Zadi S, Le Cam N, Bentejac MC, Adamowicz L, et al. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand. 1989;17(1):9\u201315.","journal-title":"J Biol Stand"},{"issue":"2","key":"8114_CR23","first-page":"175","volume":"48","author":"FL Ruben","year":"1973","unstructured":"Ruben FL, Smith EA, Foster SO, Casey HL, Pifer JM, Wallace RB, et al. Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to nigerian children. Bull World Health Organ. 1973;48(2):175\u201381.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"8114_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jmv.1890190403","volume":"19","author":"B Yvonnet","year":"1986","unstructured":"Yvonnet B, Coursaget P, Deubel V, Diop-Mar I, Digoutte JP, Chiron JP. Simultaneous administration of hepatitis B and yellow fever vaccines. J Med Virol. 1986;19(4):307\u201311.","journal-title":"J Med Virol"},{"issue":"49","key":"8114_CR25","first-page":"661","volume":"93","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of experts on immunization, October 2018 - conclusions and recommendations. Wkly Epidemiol Rec. 2018;93(49):661\u201380.","journal-title":"Wkly Epidemiol Rec"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08114-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:48:51Z","timestamp":1679863731000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08114-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8114"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08114-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"5 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The study protocol was approved by the Ad-hoc Ethics Committee of the National Commission of Health Research of the Ministry of Health of Argentina and the Pan American Health Organization Ethics Review Committee (PAHOERC Ref. PAHO-2014-07-0011). In accordance with human subjects\u2019 review procedures at the CDC, it was determined that the CDC was not formally engaged in this human-subjects research. A parent or legal guardian provided written informed consent for their child\u2019s participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}